AU Patent

AU2008314068B2 — Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent

Assigned to Roche Glycart AG · Expires 2014-01-16 · 12y expired

What this patent protects

The present invention is directed to the use of a type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with an anti-Bcl-2 active agent.

USPTO Abstract

The present invention is directed to the use of a type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with an anti-Bcl-2 active agent.

Drugs covered by this patent

Patent Metadata

Patent number
AU2008314068B2
Jurisdiction
AU
Classification
—
Expires
2014-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Roche Glycart AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.